20180524 PR financial meetings Q2 18
Category: Press release
Combined General Meeting of May 23, 2018
20180523 TG AGM 2018 EN
Transgene to Present New Clinical Data on Oncolytic Virus Pexa-Vec at ASCO 2018
20180517 PR ASCO poster accepted EN
Availability of Preparatory Documents for the Combined General Meeting (Ordinary and Extraordinary Sessions) of May 23, 2018
20180502 MISE A DISPO AG – US
€35.6 Million in Cash and Cash Equivalents as of March 31, 2018
20180426-Resultats-Q1-2018-EN
Transgene Presents Data on a Novel Viral Vector with Remarkable Anticancer Activity at AACR 2018
20180418 AACR 2018 poster PCPV – EN
Transgene to announce major clinical results in 2018 and achieve promising progress on its new oncolytic viruses
20180321-Resultats-2017-EN
Transgene to Present Data on a Novel Viral Vector with Superior Anti-Cancer Immunotherapeutic Activity at AACR 2018
20180315 PR AACR LB poster accepted
First Chronic Hepatitis B Patient Dosed in China in a Phase 1 Trial of T101 (Transgene’s TG1050 Technology)
20180117 PR FPI T101
First Patient Dosed in a Phase 2 Trial with Transgene’s TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Lung Cancer (NSCLC)
20180116 PR FPI TG4010 1L EN